1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

01 Aug 2022
Admin
News Article

Us Fda Clears Jubilant Therapeutics Ind For Novel Dual Lsd1 & Hdac6 Inhibitor Jbi-802 For Treatment Of Solid Tumours

Jubilant Therapeutics Inc, A Biopharmaceutical Company, Announced Us Food And Drug Administration (Fda) Clearance Of The Investigational New Drug Application (Ind) For Jbi-802, A Novel, Oral, Potent And Selective Dual Inhibitor Of Lsd1 And Hdac6, For The Treatment Of Small Cell Lung Cancer (Sclc), Treatment-Induced Neuro-Endocrine Prostate Cancer (Nepc) And Other Mutation-Defined Neuroendocrine Tumours.The Phase 1/2A Trial Is An Open-Label, Two-Part Dose Escalation And Expansion Study Designed To Define The Safety Profile And Preliminary Activity Of Jbi-802 In Participants With Advanced Solid Tumours. The Study Population Will Include Patients With Locally Advanced Or Metastatic Solid Tumours Whose Disease Has Failed Prior Standard Therapy. Expansion Cohorts Of Participants With Sclc, Nepc, And Other Neuroendocrine-Derived Cancers Will Be Enrolled To Obtain Additional Safety And Efficacy Data.Hari S Bhartia, Chairman, Jubilant Therapeutics Said

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!